Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Endocr Relat Cancer. 2014 May 6;21(3):R235–R246. doi: 10.1530/ERC-14-0092

Figure 2.

Figure 2

The participants at the King College, Cambridge ICI Pharmaceuticals Division Medical Symposium September 1977. The author (top) presented the new strategy, Professor Michael Baum (right) was the session chair and leader of the proposed NATO trial that was planned to advance the current 1 year adjuvant tamoxifen trials to a 2 year treatment period. Helen Stewart (left), was in the audience and had plans to compare placebo and tamoxifen at first recurrence with 5 years of immediate adjuvant tamoxifen in the Scottish trial. Both trials (NATO and the Scottish trial) were to demonstrate, for the first true, survival advantages for adjuvant tamoxifen used for longer than 1 year.

HHS Vulnerability Disclosure